Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Molecular Partners AG    MOLN   CH0256379097

MOLECULAR PARTNERS AG

(MOLN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
08/12/2019 08/13/2019 08/14/2019 08/15/2019 08/16/2019 Date
12.86(c) 12.84(c) 13.08(c) 12.28(c) 12.72(c) Last
6 761 2 704 3 830 7 285 10 245 Volume
+2.39% -0.16% +1.87% -6.12% +3.58% Change
More quotes
Financials (CHF)
Sales 2019 22,6 M
EBIT 2019 -46,5 M
Net income 2019 -45,9 M
Finance 2019 43,5 M
Yield 2019 -
Sales 2020 83,7 M
EBIT 2020 25,5 M
Net income 2020 25,9 M
Finance 2020 89,7 M
Yield 2020 -
P/E ratio 2019 -6,23x
P/E ratio 2020 11,1x
EV / Sales2019 10,1x
EV / Sales2020 2,16x
Capitalization 270 M
More Financials
Company
Molecular Partners AG is a Switzerland-based company engaged in the pharmaceuticals industry. As a biopharmaceutical company, it is active in the research and development of proteins like DARPins (Designed Ankyrin Repeat Proteins), a new class of small proteins used for the development of medicine... 
More about the company
Surperformance© ratings of Molecular Partners AG
Trading Rating : Investor Rating :
More Ratings
Latest news on MOLECULAR PARTNERS AG
04/02MOLECULAR PARTNERS : Allergan and Molecular Partners Announce Topline Safety Res..
PR
2018AMGEN : Molecular Partners Form Immuno-Oncology Collaboration
DJ
2018Molecular Partners agrees cancer immunotherapy deal with Amgen
RE
2018Molecular partners and amgen announce strategic collaboration in immuno-oncol..
TE
2018AMGEN : And Molecular Partners Announce Strategic Collaboration In Immuno-Oncolo..
PR
2018Molecular Partners' R&D Day in New York highlights progress of pipeline of DA..
TE
2018Interim management statement q3 2018
TE
2018Drugmakers tout new medicines as eye disease battle intensifies
RE
2018MOLECULAR PARTNERS REPORTS KEY FINAN : Promising MP0250 clinical data in oncolog..
TE
2018Allergan and Molecular Partners Announce Two Positive Phase 3 Clinical Trials..
TE
More news
Analyst Recommendations on MOLECULAR PARTNERS AG
More recommendations
Sector news : Bio Therapeutic Drugs
08/15European Medicines Agency Reviews Arthritis Treatment by Gilead, Galapagos
DJ
08/12REGENERON PHARMACEUTICALS : Two Experimental Ebola Drugs Reduce Mortality Rate
DJ
08/08Sarepta says adverse event report for DMD gene therapy erroneously submitted
RE
08/08AGENUS : FDA Accepts AGEN2373 IND, Triggering $7.5 Million Milestone
DJ
08/07NOVARTIS : Medicare Moves to Cover Costly Cell Therapies
DJ
More sector news : Bio Therapeutic Drugs
Chart MOLECULAR PARTNERS AG
Duration : Period :
Molecular Partners AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MOLECULAR PARTNERS AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 32,08  CHF
Last Close Price 12,72  CHF
Spread / Highest target 293%
Spread / Average Target 152%
Spread / Lowest Target 21,9%
EPS Revisions
Managers
NameTitle
Patrick Amstutz Chief Executive Officer & Director
William Matt Burns Chairman
Michael Tobias Stumpp Chief Operating Officer
Andreas Emmenegger Chief Financial Officer
Andreas Harstrick Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
MOLECULAR PARTNERS AG-33.26%267
GILEAD SCIENCES0.94%79 622
VERTEX PHARMACEUTICALS11.60%46 554
REGENERON PHARMACEUTICALS-20.52%32 073
GENMAB22.34%13 013
SAREPTA THERAPEUTICS INC14.50%9 067